Skip to content
Industry
This is research, not advice. We’re not SEBI-registered.

Park Medi World share price today

PARKHOSPSHealthcare servicesConsolidatedPrices to 20 Nov 2026Results to Sep 2026

10Y not available: listed Dec 2025
Price, 200-day average and NIFTY 500Since Dec 2025Since Dec 2025

The price is 1.6% below its 200-day average and 59 points ahead of the NIFTY 500 since listing in Dec 2025

20 Nov 2026₹238.05Since listing in Dec 2025: Park Medi World +60.9%, NIFTY 500 +1.7%
₹200₹300Feb 26May 26Aug 26Nov 26

Price growth

1Y3Y5Y10Y1YToo short3YToo short5YToo short10YToo short

EPS and P/ESince Dec 2025Since Dec 2025

EPS ₹5.93, up 3% in a year; P/E 40.1

20 Nov 2026₹5.93 EPS
Sep 25
Dec 25
Mar 26
Jun 26
Sep 26
Nov 26
₹0₹8

EPS growth

1Y3Y5Y10Y1Y+2.6%3YToo short5YToo short10YToo short

Revenue and marginsSince Dec 2025Insufficient history, from Mar 2021

Revenue up on a year for 6 quarters in a row; operating margin 20.0%, the lowest on this chart

Sep 2026 quarter₹511 crore+24.6% on ₹410 crore a year earlier · NPM 10.6%
Jun 24
Sep 24
Dec 24
Mar 25
Jun 25
Sep 25
Dec 25
Mar 26
Jun 26
Sep 26
0₹600

Revenue: 1Y change, then growth a year; margins are averages

Revenue growth1Y+22.9%3Y+10.2%/yr to Mar5Y+17.0%/yr to Mar10YToo short
OPM average3Y26.3% to Mar5Y28.1% to Mar
NPM average3Y14.9% to Mar5Y16.1% to Mar

Return on capitalInsufficient history, from Mar 2022Insufficient history, from Mar 2022

ROCE was 17.9% for the four quarters to Sep 2026, down from 38.0% in the year to Mar 2022

Four quarters to Sep 202617.9% ROCEInsufficient history: data from Mar 2022
20%30%Sep 22Sep 24Sep 26

ROCE average

1Y3Y5Y10Y1Y17.9%3Y19.8% to Mar5Y25.7% to Mar10YToo short

Profit and cashSince Dec 2025Insufficient history, from Mar 2021

Cash from operations was 118% of profit over five years, 120% in the year to Mar 2026

Yearly profit, cash from operations and free cash flow, ₹ crore

FY26₹329 crore operating cashProfit ₹274 crore · Free cash ₹209 crore
FY22
FY23
FY24
FY25
FY26
0₹400

Profit growth: 1Y change, then growth a year

1Y3Y5Y10Y1Y+12.3%3Y+6.3%/yr to Mar5Y+7.9%/yr to Mar10YToo short

ReinvestmentSince Dec 2025Insufficient history, from Mar 2021

Capex was ₹120 crore in the year to Mar 2026, 1.9 times depreciation

FY26₹120 crore capexWork in progress ₹123 crore
FY22
FY23
FY24
FY25
FY26
0₹200

Capex growth: 1Y change, then growth a year

1Y3Y5Y10Y1Y−17.2% to Mar3Y+7.0%/yr to Mar5Y−2.8%/yr to Mar10YToo short

BorrowingsInsufficient history, from Dec 2024Insufficient history, from Dec 2024

Debt ÷ equity 0.26 at 30 Sep 2026; profit covered interest 7.8x over the last four quarters

Sep 2026 balance sheet0.26 debt ÷ equityNet cash ₹67 crore
Dec 24
Mar 25
Jun 25
Sep 25
Dec 25
Mar 26
Jun 26
Sep 26
015x

Safety

Now3Y ago
Debt ÷ equity0.263Y agon/a
Int. cover7.8x3Y ago7.2x

Operating healthSince Dec 2025Since Dec 2025

Working capital fell from 40 to 28 days in 5 years

Year to Mar 202628 days working capital
0100Mar 22Mar 24Mar 26
Working cap.281Y−23Y−125Y−12
Debtor1291Y−323Y−395Y−22
Inventory41Y+13Y+15Y−43

OwnershipInsufficient history, from Dec 2025Insufficient history, from Dec 2025

FIIs own 0.88%; no figure a year earlier. Promoters hold 82.89%

Share of the company held, %, by quarter end

Sep 2026 quarter0.88% FIIsNo figure a year earlier
0%80%Mar 26Jun 26Sep 26

FIIs 1Y, FIIs 3Y, Promoters 1Y, Promoters

3Y3YToo short

Park Medi World Ltd · PARKHOSPS · Hospitals/Medical Services · price as of the 20 November 2026 close, updated every trading day · results updated weekly · research updated 14 November 2026

Park Medi World share price today: ₹238.05 at the close on 20 November 2026, up 53.7% in a year. Park Medi World (PARKHOSPS) is worth ₹10,265 crore, trades at a P/E of 40.1 and has closed between ₹143.92 and ₹299.30 over the past 52 weeks. Latest change: profit fell in the September 2026 quarter.

₹238.05Price +53.7% in a year
40.1×P/E lower than 55% of the last 11 months
₹511 CrRevenue (Sep 2026) +24.6% on a year ago
₹54.0 CrProfit (Sep 2026) −31.6% on a year ago
20.0%Operating margin −7.6 points on a year ago
17.9%ROCE four quarters to Sep 2026

Park Medi World Ltd's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer.

The main question: the share price moved +53.7% in a year while earnings per share (last four quarters) moved +2.6%. The difference came from the market paying a higher multiple.

The price is in an uptrend that has just slipped below its 200-day average, and the P/E is lower than 55% of its own last 11 months. Over the last four quarters, results have been deteriorating, with profit −31.6% on a year earlier, and 142% of the last 3 years' profit came in as cash. What will decide it: whether earnings grow into a price that has already moved.

Left out of this page: Its two data sources disagree by up to 34% on reported income across 7 comparable periods, so nothing from the second source is shown here. That is why the yearly return-on-capital-used (ROIC) line, the total-debt and debt-to-equity series and the F-score and the return-on-capital-used (ROIC) reading are missing. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data.

What is the Park Medi World share price today?

Park Medi World Ltd's share price was ₹238.05 at the close on 20 November 2026. It is in an uptrend that has just slipped below its 200-day average. That is 1.6% below its average price over the last 200 trading days.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Park Medi World Ltd is in stage 2. The phase helps read everything below.

Since its first close in our records, on 19 December 2025, it has traded between ₹144 and ₹299, and at that close it sat 61% of the way up from that low. Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 7 weeks running.

Week by week since 2025: did it beat the NIFTY 500 over the past 13 weeks?

Ahead in 27 of 44 weeks

Week by week since 2025: did it beat the NIFTY 500 over the past 13 weeks?
Week13-week return vs NIFTY 500
19 Dec 2025no NIFTY 500 reading
26 Dec 2025no NIFTY 500 reading
2 Jan 2026no NIFTY 500 reading
9 Jan 2026no NIFTY 500 reading
16 Jan 2026no NIFTY 500 reading
23 Jan 2026no NIFTY 500 reading
1 Feb 2026no NIFTY 500 reading
6 Feb 2026no NIFTY 500 reading
13 Feb 2026no NIFTY 500 reading
20 Feb 2026no NIFTY 500 reading
27 Feb 2026no NIFTY 500 reading
6 Mar 2026no NIFTY 500 reading
13 Mar 2026no NIFTY 500 reading
20 Mar 2026+38.5%
27 Mar 2026+49.1%
2 Apr 2026+44.8%
10 Apr 2026+46.2%
17 Apr 2026+45.6%
24 Apr 2026+49.6%
30 Apr 2026+54.7%
8 May 2026+64.4%
15 May 2026+42.6%
22 May 2026+43.8%
29 May 2026+51.6%
4 Jun 2026+40.9%
5 Jun 2026+41.3%
9 Jun 2026+40.9%
10 Jun 2026+32.5%
12 Jun 2026+31.3%
17 Jun 2026+17.2%
19 Jun 2026+27.0%
24 Jun 2026+21.2%
25 Jun 2026+22.0%
1 Jul 2026+17.5%
3 Jul 2026+17.2%
10 Jul 2026+7.3%
17 Jul 2026−8.1%
24 Jul 2026−4.0%
31 Jul 2026−0.6%
7 Aug 2026−5.0%
14 Aug 2026−4.0%
21 Aug 2026−4.1%
28 Aug 2026+12.7%
4 Sep 2026+2.6%
11 Sep 2026−1.8%
18 Sep 2026+0.0%
25 Sep 2026−0.1%
28 Sep 2026−2.5%
1 Oct 2026+1.0%
9 Oct 2026+5.1%
16 Oct 2026−13.1%
23 Oct 2026−17.8%
30 Oct 2026−17.2%
6 Nov 2026−10.1%
8 Nov 2026−4.9%
13 Nov 2026−12.9%
20 Nov 2026−18.9%
Each bar is one week, from 2025 to now (44 weeks with a reading). Green means the stock's return over the previous 13 weeks beat the NIFTY 500; red means it trailed. The colour is strongest at a gap of 25 percentage points or more. A gap means there is no reading for that week.

Over the last 11 months the share price moved +54% while the NIFTY 500 moved +0%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 9 October 2026. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

What changed at Park Medi World this quarter?

Three changes stood out: profit fell in the September 2026 quarter, lowest operating margin in 8 quarters and revenue up on a year earlier for 4 quarters in a row (every quarter we can compare).

  1. Profit fell in the September 2026 quarter

    Profit was ₹54 crore, -31.6% on a year earlier (₹79 crore), after 3 quarters of growth.

  2. Lowest operating margin in 8 quarters

    Operating margin was 20% in the September 2026 quarter, against 27% a year earlier.

  3. Revenue up on a year earlier for 4 quarters in a row (every quarter we can compare)

    In the September 2026 quarter revenue was ₹511 crore, +24.6% on a year earlier.

What are Park Medi World's latest quarterly results?

For July to September 2026 (the quarter ended 30 September 2026), Park Medi World reported revenue of ₹511 crore, up 24.6% from ₹410 crore a year earlier, and a profit of ₹54.0 crore, down 31.6% from ₹79.0 crore.

Park Medi World results: July to September 2026 against a year earlier

Park Medi World results: July to September 2026 against a year earlier
MeasureJuly to September 2026July to September 2025Change
Revenue₹511 crore₹410 crore+24.6%
Profit₹54.0 crore₹79.0 crore−31.6%
Earnings per share₹1.21₹1.91−36.6%
Operating margin20.0%27.6%−7.6 points

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

Park Medi World's management discussed these results on a call held on 14 November 2026; what it said is further down this page.

From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.

What is the Park Medi World share price history?

Park Medi World closed at ₹238.05 on 20 November 2026, up 53.7% from ₹154.89 a year earlier (19 December 2025). Its highest weekly close since December 2025 was ₹295.35 on 1 July 2026.

Park Medi World share price: then and now

Park Medi World share price: then and now
WhenCloseChange to 20 Nov 2026
1 week ago · 13 Nov 2026₹255.58−6.9%
1 month ago · 19 Oct 2026₹227.85+4.5%
6 months ago · 22 May 2026₹259.19−8.2%
1 year ago · 19 Dec 2025₹154.89+53.7%
Earliest weekly close in our records · 19 Dec 2025₹154.89+53.7%
Highest weekly close since December 2025 · 1 Jul 2026₹295.35−19.4%
Lowest weekly close since December 2025 · 26 Dec 2025₹145.47+63.6%

Weekly closing prices. Each change is the move from that price to the 20 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

57 weekly closes from 19 December 2025 to 20 November 2026.

What is the latest news on Park Medi World?

20 Nov 2026: Park Medi World closed at ₹238.05, down 6.9% on the week and up 4.5% on the month. 14 Nov 2026: Park Medi World held its results call for July to September 2026. Management guided: FY27 revenue close to ₹2,050 crore with H2-weighted ramp.

Earlier

  • Results for July to September 2026: Revenue up 24.6% and profit down 31.6% on a year earlier.

What dividend does Park Medi World pay?

Park Medi World has paid no dividend on the exchange since its first close in our records (19 December 2025), the start of the period we checked.

No. Park Medi World Ltd paid out 0% of its profit as dividends in each of its last 6 reported years, so there is no payout history to show. That comes from the filed annual statements, not an estimate.

From the exchange corporate-actions record, read 20 November 2026.

What did Park Medi World management say on the latest results call?

On the call for July to September 2026, held on 14 November 2026, Park Medi World's management guided: FY27 revenue close to ₹2,050 crore with H2-weighted ramp.

“The company currently has 2,300 beds under execution, which are expected to become operational by December 2028, taking the total bed capacity to 6,590 beds from 4,290 beds as of September 30, 2026.”Rajesh Sharma, Group CFO, on the call for July to September 2026

What management guided

  • FY27 operating profit ₹540-550 crore (management said profit then corrected to operating margin)
  • FY28 topline close to ₹2,550 crore, new FY27 beds about 20% revenue and 10-12% operating profit.
  • Exit Mar-27 at 5,040 beds (1,430 FY27 adds; 680 done, 750 rest); add 1,000 FY28 across 4 units; 6,590 Dec-28.
  • ₹750 crore capital spending for 2,300 beds to Dec-28 at ₹30-35 lakh per bed; Allahabad 560-bed net ₹125-130 crore after reimbursement illustrates blend.

Management’s own plans and goals, from our notes of the call. A plan is not a result.

Source: the call transcript.

From the call for July to September 2026, 14 November 2026.

What to watch in Park Medi World's next results?

When Park Medi World reports October to December 2026, these are the 4 checks that show whether the story is still on course. First: Blended operating profit recovery as new units season toward year-end streamlining promise - check next print margin path.

Management raised each of these on the latest results call.

  • Blended operating profit recovery as new units season toward year-end streamlining promise - check next print margin path.
  • Consumables ratio normalization after one-time food-service and mix hit - check next quarter cost trend.
  • Receivable days retracing from September peak on October collection momentum - check year-end band adherence.
  • Rest-of-year bed commissioning staying on schedule toward flagged exit capacity - check commissioning intimations.

Which stock lists is Park Medi World on?

Park Medi World is on 2 of our India lists: Multibagger study list and Healthcare & hospital stocks.

Is Park Medi World profitable?

Park Medi World Ltd earned ₹54.0 Cr of net profit in the Sep 2026 quarter, −31.6% on the same quarter a year earlier. Full-year FY26 profit was ₹274 Cr. Over 5 years profit has grown 7.9% a year on average. The Sep 2026 quarter's profit is 10.6% of that quarter's revenue. The same quarter a year earlier earned ₹79.0 Cr.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

For the full year, FY26 profit was ₹274 Cr (+27.4% on the year before).

Why profit moved: revenue changed +24.6% on a year earlier and the margin moved −7.6 percentage points. Sales did the work while the margin got thinner.

On average over the last four quarters, profit changed +16.6% and revenue +22.9%. Profit is growing slower than sales: rising costs are taking part of the growth.

FY26-Q4. Operating profit expanded faster than revenue, with the summary's revenue and profit-growth figures requiring correction.

Why-sources: our stock research file (10 October 2026) and the company’s own results for those quarters.

How much revenue does Park Medi World make, and is it growing?

Park Medi World Ltd reported ₹511 Cr of revenue in the Sep 2026 quarter, +24.6% on the same quarter a year earlier. That is the 4th quarter in a row with growth on the year before. Over 5 years it has grown 17.0% a year on average. The last full year, FY26, came in at ₹1,679 Cr.

Revenue is everything the company billed its customers in the period.

Why this happened. The latest schedule identifies Palam Vihar and Zirakpur before Narela and Kanpur. The Operating Leverage Catapult applies as patient volumes absorb installed capacity, but pre-opening clinician costs and ramp spending can offset the benefit. Existing facilities have already contributed to revenue growth; the remaining contribution comes from commissioning and subsequent utilization. Competitor responses, referral capture and hospital-level incremental cash returns are not quantified in the supplied calls. New formats require separate economics, and their beds should not be valued as identical to wholly owned beds.

The last four reported quarters add to ₹1,857 Cr.

FY26 revenue was ₹1,679 Cr, +20.4% on the year before.

Recent pace: the last four quarters grew +22.9% on average, against 17.0% a year over the longer run, so this year is growing faster than its own long-run rate.

FY26-Q4. Operating profit expanded faster than revenue, with the summary's revenue and profit-growth figures requiring correction.

Why-sources: our stock research file (10 October 2026) and the company’s own results for those quarters.

Watch next

Metric
Commissioning and hospital ramp
Threshold
Launch dates move again or mature-hospital demand fails to absorb the additional capacity.
Which result
the next result

How much of every ₹100 of sales does Park Medi World keep?

Park Medi World Ltd's operating margin was 20.0% in the Sep 2026 quarter, 7.6 percentage points lower than the same quarter a year ago. Across 6 years it has been between 25.3% and 40.3%. The latest quarter is below every full year in that period.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why this happened. The Value Chain Climb applies because advanced specialties contribute a material share of revenue and procedure categories are named. The patient pays for more complex care, while Park retains the benefit only after clinician, equipment and treatment costs. The revenue mix shift has already occurred; further profit improvement is a forecast rather than a measured bridge. Management describes procurement and employed clinicians as supporting economics, but has not separated their contributions. Local demand and specialist availability can constrain the next stage.

Why the margin moved: operating margin changed −7.6 percentage points on the year while gross margin changed −5.6 points. So the drop came mostly from the gross margin, which means input costs and prices charged.

FY26-Q4. Operating profit expanded faster than revenue, with the summary's revenue and profit-growth figures requiring correction.

Why-sources: our stock research file (10 October 2026) and the company’s own results for those quarters.

Watch next

Metric
Advanced-care mix
Threshold
Advanced-care revenue stops progressing or its additional costs prevent a contribution to consolidated profit.
Which result
the next result

Is Park Medi World's profit turning into cash?

Over the last 3 years, 142% of Park Medi World Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹329 Cr of operating cash against ₹274 Cr of profit. After ₹120 Cr of spending on assets, ₹209 Cr was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 142% of profit came in as cash: the cash cycle got 79 days shorter between FY21 and FY26, so cash that used to wait in the business now arrives sooner.

What to look at next: the bigger use of cash is spending on new assets, at 2.0× depreciation over three years. The next section checks what that spending is building.

Where does Park Medi World's cash go?

Park Medi World Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was −2 days in FY26, down from 77 days in FY21. It spent ₹336 Cr on assets over the last 3 years. Customers take 129 days to pay, and stock sits for 4 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹1,679 Cr, each day of that cycle ties up about ₹4.6 Cr, so roughly −₹9.0 Cr is tied up in the business at any time.

FY26: customers took 129 days to pay and stock sat for 4 days, about 0.1 months of sales sitting as stock, for a full cycle of −2 days, shorter than FY21's 77.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 4 days. Customers pay about 129 days after that. Suppliers are paid at 134 days. Together that makes the −2-day cycle.

Spending on assets: ₹336 Cr over the last 3 years, against ₹170 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹123 Cr (FY26): assets paid for that are not earning yet.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

What is Park Medi World's P/E ratio, and how does it compare with its own history?

Park Medi World Ltd's P/E is 40.1×, in the middle of its own history: higher than 45% of past readings. Its usual P/E (the middle reading) is 42.1×, over 11 months of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

40.1×P/E · lower than 55% of its last 11 months

Why the multiple is where it is: over the past year earnings per share moved +2.6% while the price moved +53.7%. The price did better than earnings, which pushed the multiple up within its own range.

In short: the multiple is about average against its own past, so the earnings trend underneath matters more than the multiple.

Is the Park Medi World business getting better or worse?

Park Medi World Ltd's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 4 quarters of 1 measure, with some gaps.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

FallingROCE · latest (four quarters to Sep 2026) 17.9%, range 17.9% to 31.0%

Why it matters: with too little history, we say so rather than guess a direction.

One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result.

The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone.

There are fewer than eight usable quarters, so this page does not guess a direction from so little history.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the share price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

Compound annual growth rate (%)
Measure1yr3yr5yr10yr
Revenue+20.4%+10.2%+17.0%—
Profit+27.4%+6.3%+7.9%—
EPS+13.9%+1.6%+8.2%—
+24.6%Revenue growth (Sep 2026) · latest quarter against a year ago
−31.6%Profit growth (Sep 2026) · latest quarter against a year ago
17.0%Revenue, 5 years · yearly growth over the long run

What is the Park Medi World story, and has it been checked?

Park Medi World Ltd's story is not scored yet against the checks our research set on 10 October 2026. Where it sits in its own cycle: mid expansion.

NOT YET CHECKED

Our read, 10 October 2026. Park's hospital expansion can extend operating growth, but commissioning slippage, cash reinvestment and an unreconciled revenue roadmap make delivery more useful than headline capacity goals.

From the numbers. The business remains in an expansion phase, with commissioned assets ramping and further launches ahead; the supplied price curve is stage 2. The authoritative current-segment object is absent, so the matrix label is…

From the price. Price stage 2, week 41, above its 200-day line.

Where they disagree. The business remains in an expansion phase, with commissioned assets ramping and further launches ahead; the supplied price curve is stage 2. The supplied price study already records an 83% annual run-up, so this is not described as an unrecognized early price move.

What is not proven yet. Consolidated operating margin below 22% for two consecutive reported quarters, alongside blended occupancy remaining below 55% through Q3 FY27, would show that expansion is eroding the base business rather than producing a viable ramp.

The test written in advance. Commissioning and guidance credibility. Measured by: Commissioning and guidance credibility Narela remains unopened after February 2027 or year-end capacity falls below 5,040 beds. by the next result.

The test written in advance. Occupancy and margin dilution. Measured by: Occupancy and margin dilution Operating margin below 22% for two consecutive quarters alongside occupancy below 55% through Q3 FY27. by the next result.

What the company does. Revenue and operating profit are rising together; lower interest and tax also helped the latest profit print, so its growth should not all be attributed to hospital operating leverage. The latest plan adds owned hospitals, an O&M hospital and a PPP project, creating identifiable forward work but changing the economics of the historical ownership model.

The key numbers to watch, and the level that would change the picture

The key numbers to watch, and the level that would change the picture
MeasureNowWhy it mattersWhat to watch
Commissioning and hospital rampHIGHNamed launches provide forward capacity, while the revenue contribution depends on patient absorption rather than installed beds…Launch dates move again or mature-hospital demand fails to absorb the additional capacity.
Government tariff implementationMEDIUMRevised tariffs can increase revenue, but management intends to reinvest part of the benefit.Allied agencies defer implementation or reimbursement offsets absorb the revenue benefit.
Advanced-care mixMEDIUMAdvanced procedures have reached revenue scale, although their incremental margin contribution is unquantified.Advanced-care revenue stops progressing or its additional costs prevent a contribution to consolidated profit.

Everything further down this page is evidence for or against these.

The numbersmid-way through a rise in resultsFY26-Q2 to FY27-Q1
The pricerising, above the 200-day averageFY26-Q2 to FY27-Q1
The whymultiple near its usual level, earnings turning upFY26-Q2 to FY27-Q1

FY26-Q2FY27-Q1

What the surface reading misses. The surface reading is: Profit increasing faster than revenue looks like operating leverage. The research reads it further: Operating profit increased, but lower interest and tax also helped reported profit; the rounded operating-margin cell was unchanged.

What the surface reading misses. The surface reading is: Higher margin and profit suggest a capacity-led earnings acceleration. The research reads it further: Operating profit grew faster than revenue, while the tax rate increased rather than providing a year-earlier benefit.

  • 1 · Operating leveragebuilding
  • 2 · Value-added mixbuilding
  • 3 · Management changebuilding
  • 4 · Paying down debtquiet
  • 5 · Regulatory approvalquiet
  • 6 · Order-book winsquiet
  • 7 · Consolidationbuilding
  • 8 · Demerger or value unlockquiet
  • 9 · Buybackquiet
  • 10 · New geographiesquiet
  • 11 · More business from existing customersquiet
  • 12 · New product launchquiet
  • 13 · Mandatory normsquiet
  • 14 · A bigger market to servequiet
  • 15 · Market-share gainsquiet
  • 16 · Asset qualityquiet

Lever 7 · Consolidation: building. Named launches provide forward capacity, while the revenue contribution depends on patient absorption rather than installed beds alone. What proves it keeps working: Commissioning and hospital ramp. It stops working if Launch dates move again or mature-hospital demand fails to absorb the additional capacity.

Lever 3 · Management change: building. Revised tariffs can increase revenue, but management intends to reinvest part of the benefit. What proves it keeps working: Government tariff implementation. It stops working if Allied agencies defer implementation or reimbursement offsets absorb the revenue benefit.

Lever 2 · Value-added mix: building. Advanced procedures have reached revenue scale, although their incremental margin contribution is unquantified. What proves it keeps working: Advanced-care mix. It stops working if Advanced-care revenue stops progressing or its additional costs prevent a contribution to consolidated profit.

Sources: our stock research file (10 October 2026) · quarterly results through Sep 2026 · the company’s own earnings calls. The story check is re-scored every results season; the record below never changes.

The whole page in one table. Each row links to its section.

The whole page in one table. Each row links to its section.
SectionWhere it is nowThe one thing to watch next
Revenue₹460 CrCommissioning and hospital ramp
Ownershipsee the sectionGovernment tariff implementation
Margin28%Advanced-care mix

Did Park Medi World management deliver what it promised?

What Park Medi World Ltd's management promised, against what actually happened: 4 promises on the record. Read straight from the company’s own earnings calls. A promise that slipped stays on this page after it is met.

FY27 Profit Guidance Requires Reconciliation · 14 November 2026. In Aug 2026, management guided to FY'27 PAT of Rs.360 crores. In Nov 2026, it stated PAT of 540-550 crores, more than 50% above the prior goal, and then corrected itself with EBITDA margin, sorry, leaving it unclear whether this was a PAT revision or a correction to EBITDA guidance.

Bed Expansion Goals Have Shifted Without Reconciliation · 14 November 2026. The May and Aug 2026 calls set materially lower capacity milestones: 5,460 beds by March 2028 and then 5,740 beds by end FY28. The Nov 2026 call now states 6,590 beds by December 2028 with 2,300 beds under execution, but does not explain whether the 850 additional beds are new projects or a timing change.

Term Debt Has Increased Sharply Versus Prior Funding Expectations · 14 November 2026. The May and Aug 2026 calls portrayed the expansion as fully funded and reported term debt near 26-28 crores. Nov 2026 reports 178 crores on the same excluding-lease measure, nearly seven times higher, without explaining the financing change.

New-Hospital Margin Outlook Reversed · 14 November 2026. In Aug 2026, management said it did not expect any loss from the newly started Agra and Panchkula units and expected them to be EBITDA-positive in FY27. In Nov 2026, the new-unit cohort reported a negative 8% EBITDA margin in H1 FY27; although management cited normal ramp-up and the cohort now includes Rudrapur, it did not provide a unit-level bridge to reconcile the result with the earlier no-loss assurance.

Every quote above is taken word for word from the company’s own earnings calls.

What is Park Medi World management's track record?

The capacity miss is partial, not a flagship failure; capital spending scope and financial-roadmap differences are unresolved, not proved false statements. Full-downturn conduct is not established.

Regulatory and governance record

Historical rating-agency non-cooperation is a disclosure concern, not a regulator finding of fraud. The filing index alludes to tax raids without naming an authority, allegation or amount; it is an unverified lead, not a demonstrated large live case.

Checked 14 October 2026.

How much does Park Medi World earn on its capital?

Park Medi World Ltd earned a ROCE of 19% in FY26. We cannot compare its return on capital used with its cost of capital from the data we have. It comes from a 16.3% net margin and 0.60× asset turnover (sales divided by assets).

Return on capital employed (ROCE) is the profit the whole business earns on all the money in it, from shareholders and lenders together. It is the best single test of whether growth adds value or just size.

Why the return is what it is (FY26): a 16.3% net margin × 0.60× asset turnover × 1.38× leverage (assets divided by equity) ≈ 13.5% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed.

The quarterly return lines and the return-on-capital-used (ROIC) line, which only the second data source has, are not shown on this page: its two data sources disagree by up to 34% on reported income across 7 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data.

Does Park Medi World have too much debt?

Park Medi World Ltd had ₹364 Cr of borrowings against ₹2,022 Cr of equity in FY26, so its debt is 0.18× its equity. Its operating profit is 7 times its interest bill. Over 5 years borrowings went from ₹292 Cr to ₹364 Cr. Over the last 3 of those years it spent ₹336 Cr on assets.

Debt-to-equity shows how much of the business is paid for with borrowed money. Interest cover shows how many times operating profit pays the interest bill. Low debt and high cover are the safe combination.

Part of the spending on assets is being paid for with borrowed money.

The total-debt and debt-to-equity series, which only the second data source has, are not shown on this page: its two data sources disagree by up to 34% on reported income across 7 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data.

What is the Park Medi World shareholding pattern?

No group of Park Medi World Ltd's owners changed its stake by a full percentage point over the last 4 quarters. This uses the four owner groups that companies report every quarter; nothing is guessed between filings.

Who owns the company each quarter: promoters (the founders or controlling owners), foreign institutions, domestic institutions such as mutual funds, and the public. When people close to the business steadily raise their stake, that is worth noticing; a quiet list is also an answer.

Why this happened. Allied-agency implementation is the external trigger; Park's payer exposure determines how much of it reaches revenue. Management explicitly described equipment, repairs and maintenance as uses of the benefit, so revenue uplift cannot be treated as equal profit uplift. Some implementation has already begun, while the remaining timing depends on agencies. The supplied evidence does not establish competitors' pricing response or the net incremental cash contribution.

Watch next

Metric
Government tariff implementation
Threshold
Allied agencies defer implementation or reimbursement offsets absorb the revenue benefit.
Which result
the next result

How far is Park Medi World from balance-sheet trouble?

For Park Medi World Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

How does Park Medi World rank in its industry?

48.5 out of 100, rank 3 of 8 in Hospitals/Medical Services, with 55% of the evidence available.

Park Medi World Ltd scores 48.5 out of 100 against the 8 companies it is compared with in Hospitals/Medical Services, ranking 3. Some evidence is missing, so the score is pulled toward the middle on purpose.

The three scored parts add up to the total exactly: 19 + 17.3 + 12.2 = 48.5 (no relative-strength reading this week; its 20 points are shared across the other three). This is the same number shown on the industry page; it is worked out once for the whole group and read here.

What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector.

Which companies is Park Medi World compared with?

Park Medi World ranks 3 of 8 Hospitals/Medical Services companies on the 4-Factor Sector Score, with 48.5 out of 100.

  1. 1Dr Agarwals Health Care LtdAGARWALEYE · turning · Evidence leans up · 60% evidence58.9out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 28.6/35 · Revenue 25.9% · Profit 42.1% · Operating margin change 0 points · 95% evidenceCapital efficiency 9.3/25 · ROCE 10.9% (year to Mar 2026) · Operating margin 26.9% · 76% evidenceValuation 8.5/20 · P/E 97.4× · PEG — · 15% evidenceRelative strength 12.5/20 · Strength vs its industry (price vs its 52-week average, weekly) — · Strength vs NIFTY 500 (same reading) 11.5% · 1 year 12.1% · 25% evidence · 9 of 12 weeks aheadExact sum: 28.6 + 9.3 + 8.5 + 12.5 = 58.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  2. 2Gujarat Kidney & Super Speciality LtdGKSL · breaking out · Evidence leans up · 63% evidence50.5out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 23.8/43.75 · Revenue 100% · Profit 68.2% · Operating margin change -12.8 points · 100% evidenceCapital efficiency 15.5/31.25 · ROCE 14.5% (year to Mar 2026) · Operating margin 26.8% · 100% evidenceValuation 11.2/25 · P/E 61.9× · PEG — · 15% evidenceRelative strength: no reading this week · its 20 points are shared across the other threeExact sum: 23.8 + 15.5 + 11.2 = 50.5 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: There is no relative-strength reading for this week, so the score is built from earnings, capital efficiency and valuation alone.
  3. 3Park Medi World Ltd this pagePARKHOSPS · quiet · Too little evidence to rank firmly · 55% evidence48.5out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 19.0/43.75 · Revenue 22.9% · Profit 12.3% · Operating margin change -7 points · 95% evidenceCapital efficiency 17.3/31.25 · ROCE 19.5% (year to Mar 2026) · Operating margin 20% · 76% evidenceValuation 12.2/25 · P/E 40.1× · PEG — · 15% evidenceRelative strength: no reading this week · its 20 points are shared across the other threeExact sum: 19 + 17.3 + 12.2 = 48.5 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose.
  4. 4Gaudium IVF and Women Health LtdGAUDIUMIVF · quiet · Evidence leans down · 63% evidence46.1out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 9.5/43.75 · Revenue 22.9% · Profit 3.9% · Operating margin change -7.4 points · 100% evidenceCapital efficiency 22.8/31.25 · ROCE 29.5% (year to Mar 2026) · Operating margin 36% · 100% evidenceValuation 13.8/25 · P/E 30.4× · PEG — · 15% evidenceRelative strength: no reading this week · its 20 points are shared across the other threeExact sum: 9.5 + 22.8 + 13.8 = 46.1 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: There is no relative-strength reading for this week, so the score is built from earnings, capital efficiency and valuation alone.
  5. 5Nephrocare Health Services LtdNEPHROPLUS · quiet · Evidence leans down · 64% evidence44.4out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 19.2/43.75 · Revenue 24.8% · Profit 100% · Operating margin change -5 points · 74% evidenceCapital efficiency 10.5/31.25 · ROCE 15.3% (year to Mar 2026) · Operating margin 20.8% · 100% evidenceValuation 14.7/25 · P/E 51.4× · PEG 1.22 · 65% evidenceRelative strength: no reading this week · its 20 points are shared across the other threeExact sum: 19.2 + 10.5 + 14.7 = 44.4 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: There is no relative-strength reading for this week, so the score is built from earnings, capital efficiency and valuation alone.
  6. 6KRM Ayurveda LtdKRMAYURVED · Too little evidence to rank firmly · 38% evidence64.4out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 23.5/43.75 · Revenue — · Profit — · Operating margin change 12 points · 32% evidenceCapital efficiency 26.5/31.25 · ROCE 35.3% (year to Mar 2026) · Operating margin 37.2% · 95% evidenceValuation 14.4/25 · P/E 18.7× · PEG — · 15% evidenceRelative strength: no reading this week · its 20 points are shared across the other threeExact sum: 23.5 + 26.5 + 14.4 = 64.4 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose.
  7. 7Unihealth Hospitals LtdUNIHEALTH · quiet · Too little evidence to rank firmly · 42% evidence53.5out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 17.7/35 · Revenue — · Profit — · Operating margin change -4 points · 15% evidenceCapital efficiency 16.7/25 · ROCE 24.5% (year to Mar 2026) · Operating margin 33.9% · 57% evidenceValuation 10.2/20 · P/E 32.9× · PEG — · 15% evidenceRelative strength 8.9/20 · Strength vs its industry (price vs its 52-week average, weekly) -0.7% · Strength vs NIFTY 500 (same reading) 6.3% · 1 year 53.1% · 100% evidence · 5 of 12 weeks aheadExact sum: 17.7 + 16.7 + 10.2 + 8.9 = 53.5 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose.
  8. 8Credent Connect N Care LtdCREDENT · Too little evidence to rank firmly · 38% evidence50.5out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 21.0/43.75 · Revenue — · Profit — · Operating margin change 0 points · 32% evidenceCapital efficiency 16.2/31.25 · ROCE 21.5% (quarter to Sep 2026) · Operating margin 13% · 95% evidenceValuation 13.3/25 · P/E 32.3× · PEG — · 15% evidenceRelative strength: no reading this week · its 20 points are shared across the other threeExact sum: 21 + 16.2 + 13.3 = 50.5 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose.

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read.

In this ranking every company's P/E uses its own latest official close and its last four filed quarters, the same rule as the top of this page. ROCE here is each company's last full year, as labelled, so it can differ from the four-quarter ROCE above. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section.

Related companies: Hospitals/Medical Services, all 8 compared on one page.

Which companies are close to Park Medi World in size?

Park Medi World is the 2nd largest of 7 Hospitals/Medical Services companies on Sector Alpha by market value (at the 20 November 2026 close). Just above it: Dr Agarwals Health Care. Just below it: Nephrocare Health Services, Gujarat Kidney & Super Speciality, Unihealth Hospitals, Gaudium IVF and Women Health and KRM Ayurveda.

Hospitals/Medical Services companies close in size

  1. Dr Agarwals Health Care Ltd ₹17,545 crore
  2. Park Medi World Ltd ₹10,275 crore
  3. Nephrocare Health Services Ltd ₹6,595 crore
  4. Gujarat Kidney & Super Speciality Ltd ₹1,177 crore
  5. Unihealth Hospitals Ltd ₹844 crore
  6. Gaudium IVF and Women Health Ltd ₹725 crore
  7. KRM Ayurveda Ltd ₹468 crore

All 7 Hospitals/Medical Services companies, largest first

Companies close in size in other industries

  1. Whirlpool of India Ltd ₹10,397 crore · Consumer Electronics
  2. Viyash Scientific Ltd ₹10,314 crore · Pharma - Animal
  3. Park Medi World Ltd ₹10,275 crore
  4. Tips Music Ltd ₹10,275 crore · Music Licensing
  5. Symbiotec Pharmalab Ltd ₹10,272 crore

What else do people ask about Park Medi World?

What is Park Medi World's share price today?

Park Medi World Ltd's share price is ₹238.05, +53.7% over the past year. The whole company is worth ₹10,265 Cr on the market.

In the last 52 weeks it traded between ₹144 to ₹299; today it is 61% of the way up from the low, 1.6% below its 200-day average (as of 20 November 2026).

What were Park Medi World's latest quarterly results?

Park Medi World Ltd reported revenue of ₹511 Cr and net profit of ₹54.0 Cr for the Sep 2026 quarter. Revenue rose 24.6% and profit fell 31.6% compared with a year earlier. Earnings per share were ₹1.21.

The operating margin was 20.0%, 7.6 percentage points lower than a year earlier (as of 20 November 2026).

What is Park Medi World's market cap?

Park Medi World Ltd's market capitalisation is ₹10,265 Cr at a share price of ₹238.05. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 20 November 2026).

How is Park Medi World performing?

Park Medi World Ltd's share price is in an uptrend that has just slipped below its 200-day average. In its latest quarter, revenue rose 24.6% and profit fell 31.6% compared with a year earlier. This describes what the data did, not a rating (as of 20 November 2026).

Will Park Medi World's share price go up?

This page does not forecast Park Medi World Ltd's share price. What it shows instead: the share price is ₹238.05, and it has been rising for 41 weeks. Its P/E of 40.1× is higher than 45% of its own last 1 years (as of 20 November 2026).

Who owns Park Medi World?

Promoters own 82.9% of Park Medi World Ltd, foreign institutions 0.9%, domestic institutions 8.2% and the public 8.0% (latest quarter). No group of owners changed its stake by a full point over the last two years (as of 20 November 2026).

Does Park Medi World have too much debt?

No, Park Medi World Ltd has little debt: its debt is 0.26× its equity, and its operating profit is 8 times its interest bill. At Sep 2026 borrowings were ₹552 Cr against equity of ₹2,159 Cr.

So the returns on this page come from the business, not borrowed money (as of 20 November 2026).

Where is Park Medi World in its business cycle?

Park Medi World Ltd's FY26 operating margin was 26.6%, against a 6-year range of 25.3% to 40.3%. The latest quarter was 20.0%, below the bottom of its own yearly range in the latest quarter, a low point in its cycle.

Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 20 November 2026).

What could break the Park Medi World story?

The main question: the share price moved +53.7% in a year while earnings per share (last four quarters) moved +2.6%. The difference came from the market paying a higher multiple.

On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 20 November 2026).

Is Park Medi World a stock worth studying right now?

What the numbers show: Park Medi World Ltd's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: whether earnings grow into a price that has already moved.

Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 20 November 2026).

Is there a Park Medi World share price forecast for 2026?

What management itself guided: FY27 revenue close to ₹2,050 crore with H2-weighted ramp.

Where does this page get Park Medi World's management information?

From Park Medi World's results calls, its filings and public records on governance, each dated on the page. Management’s plans are shown as plans, never as results.

Where do these numbers come from?

Sector Alpha, written by code from the published numbers. Data as of 20 November 2026.

Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.

See the plain-text version of this page.

More lists

Every Sector Alpha list, grouped

X · Instagram · YouTube · About · Newsletter · Newsletter archive
This is research, not advice. We’re not SEBI-registered.